REGEN BIOPHARMA, INC. (RGBP)

Every figure this model derived for RGBP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 239 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 287,587 AssetsCurrent 2026-06-30
current liabilities 6,165,793 LiabilitiesCurrent 2026-06-30
equity -5,878,206 StockholdersEquity 2026-06-30
interest expense 170,268 InterestExpenseNonoperating 2026-06-30
ocf -445,249 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 236,561 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 0 ShareBasedCompensation 2024-09-30

The ratios

The figures themselves rather than their scores — what somebody looking up RGBP on one particular measure came for.

RatioValue
cash operating margin-339.81
current ratio0.06
current ratio reported0.05
deferred revenue growth-9.24
dilution pct472.96
fcf margin-188.22
growth cv1.92
interest cover-4.72
operating margin-339.81
owner earnings margin-188.22
revenue growth0.0
revenue growth per share-82.55
rule of 40-339.81
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about RGBP's figures. Written by the derivation as it ran, not added afterwards.